Fig. 3: Increased MSI2 RNA binding activity in LSCs. | Nature Communications

Fig. 3: Increased MSI2 RNA binding activity in LSCs.

From: HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells

Fig. 3: Increased MSI2 RNA binding activity in LSCs.

a Number of MSI2-HyperTRIBE significant edit sites and their distribution on genes in LSKs and LSCs. Number of target genes in each cell type is shown on top of the bars. n = 3. b Overlapping of target genes in LSKs and LSCs: 2506 shared, 1656 LSC unique targets, and 359 LSK unique targets. c Differential editing of shared sites, represented by Log2 fold change of diff.frequency in LSCs and in LSKs. d Violin plot presenting log2 fold change of gene expression in LSCs and LSKs (overexpressing MIG) of shared targets, LSC unique targets (n = 1651) and LSK unique targets (n = 359). One-sided Wilcoxon test. ****p < 0.0001. Plot center lines show the median, box limits denote upper and lower quartiles, whiskers represent 1.5× interquartile range and individual points show outliers. e Percentage of gene expression (GE) independent targets in shared, LSC unique and LSK unique target groups from b. f Clustering of diff.frequency for top gene targets with diff.frequency of at least 0.6 in LSKs and LSCs (left panel). Only genes with diff.frequency significantly different (LSC vs LSK, beta-binomial test), are plotted. Matched number of edit sites for each target (per row) (the middle panel) and corresponding expression level in LSKs versus LSCs (right panel). g Total number of significant RNA-seq Gene and Drug signatures (FDR < 0.05) enriched in LSK and LSC unique targets. h Top significant RNA-seq Gene and Drug signatures enriched in LSK unique targets (359 genes) using ENRICHR analysis. FDR < 0.05 for all indicated pathways. i Top significant RNA-seq Gene and Drug signatures enriched in LSC unique targets (1656 genes) using ENRICHR analysis. FDR < 0.05 for all indicated pathways. j Gene expression (GE) independent RNA-seq Gene and Drug signatures of shared targets in LSKs and LSCs. Full list of shared target genes in b is filtered with log2fc (LSC-MIG/LSK-MIG) ≤ 1.2. k GE independent signature of RNA-seq Gene and Drug signatures of LSC unique and LSK unique targets. *FDR < 0.05.

Back to article page